Aspen Germany GmbH markets, trades and distributes pharmaceutical products in the German market and is a wholly owned subsidiary of Aspen Pharma Ireland Limited (group: Aspen Pharmacare Holdings Ltd.). In fiscal year 2022/2023 the company reported revenues of EUR 31,670,098.13 and employed an average of 40 staff. The commercial portfolio focuses on anaesthetics, high‑potency cytotoxic products and other global branded products; leading brands in 2022/2023 were Xylocaine (6,888 TEUR), Citanest (5,535 TEUR) and Emla (4,590 TEUR). The business operates across regulated Rx channels and the OTC/private market, and management cites portfolio optimization and brand differentiation to improve efficiency and margins.
Vermarktung, Handel mit und Vertrieb von pharmazeutischen Produkten, einschließlich der Beantragung und Einholung aller notwendigen öffentlich-rechtlichen Genehmigungen, insbesondere einer Großhandelserlaubnis
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 216445 (as of 7 October 2026)
Source: German Commercial Register (Handelsregister) München Local Court, HRB 216445 (as of 7 October 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 216445 (as of 7 October 2026)
Sign in to view detailed salary and cost trends.
